Published in Cancer Weekly, August 2nd, 2005
The NDA seeks accelerated approval for the use of Genasense in combination with fludarabine plus cyclophosphamide for the treatment of patients with chronic lymphocytic leukemia (CLL) who have previously received fludarabine. Genasense has received fast track designation by the FDA in CLL, meaning the indication represents an unmet medical need. Fast track designation enables the company to submit the NDA on a "rolling"...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly